Low HER2 expression (IHC 0 or 1+) was detected in the 279 ... Sixty-five samples were analyzed by FISH for HER2 amplification, including all of the 26 equivocal (IHC 2+) tumors, the 15 positive ...

Within the negative groups, which ones are HER2-low, that would be 1+ and 2+ — the 2+, of course, being FISH negative — those would be the HER2-low that we are more familiar with, but now the ...

Within the negative groups, which ones are HER2-low, that would be 1+ and 2+ — the 2+, of course, being FISH negative — those would be the HER2-low that we are more familiar with, but now the ...

However, up to 55% of all patients with breast cancer have tumours with an IHC score of one or two – the HER2-low range included in DESTINY Breast-04. Approval in that broader patient range ...

If your doctor has confirmed your cancer is HER2 ... low response rates. But this drug showed very impressive response rates –greater than 40% for most gynecologic cancers with 2+ IHC scores ...

The drug is now cleared for use in adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining ...

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...